GlassScriptPhysician profile
Anil Regmi
NPI 1346478245
$1,623.85
in general payments reported to CMS, 2019-2025
17 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $112 · 2021: $172 · 2022: $24.78 · 2023: $168 · 2024: $290 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $431.04 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $210.41 | 2019-2025 | Nulojix |
| Genzyme Corporation | $187.64 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $118.98 | 2025 | |
| Vifor Pharma, INC. | $109.92 | 2021-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $84.14 | 2020-2021 | |
| Calliditas Therapeutics US INC. | $74.97 | 2023 | Tarpeyo |
| Travere Therapeutics, INC. | $71.26 | 2023-2025 | Filspari |
| Novo Nordisk INC | $70.31 | 2024-2025 | Ozempic, Wegovy |
| Veloxis Pharmaceuticals, INC. | $61.57 | 2020-2025 | Envarsus |
| La Jolla Pharmaceutical Company | $45.53 | 2023 | Giapreza |
| Nuwellis, INC. | $37.47 | 2021 | |
| Amgen INC. | $37.01 | 2025 | Krystexxa |
| Mallinckrodt Enterprises LLC | $31.50 | 2019 | |
| Abiomed | $19.86 | 2024 | Impella |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.61 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Regmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.